{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma&page=2", "query": { "condition": "Clear Cell Renal Cell Carcinoma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Clear+Cell+Renal+Cell+Carcinoma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-07T19:33:20.842Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03501381", "title": "High Dose IL 2 and Entinostat in RCC", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "Entinostat", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roberto Pili", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2018-05-24", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2023-09-01", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 5, "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03501381" }, { "nct_id": "NCT00405366", "title": "Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "sorafenib tosylate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-11", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00405366" }, { "nct_id": "NCT00096629", "title": "Vaccine Therapy in Treating Patients With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "human prostate-specific membrane antigen plasmid DNA vaccine", "type": "BIOLOGICAL" }, { "name": "mouse prostate-specific membrane antigen plasmid DNA vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2003-11", "completion_date": "2018-04", "has_results": false, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00096629" }, { "nct_id": "NCT00566995", "title": "Phase II Study of Vandetanib in Individuals With Kidney Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cancer", "Von Hippel Lindau" ], "interventions": [ { "name": "ZACTIMA (Vandetanib) (ZD6474)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 37, "start_date": "2008-02-07", "completion_date": "2015-03", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00566995" }, { "nct_id": "NCT01638533", "title": "Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Hematopoietic and Lymphoid Cell Neoplasm", "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Neuroendocrine Neoplasm", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Colorectal Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Pancreatic Carcinoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-08-03", "completion_date": "2020-09-01", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 11, "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01638533" }, { "nct_id": "NCT03229278", "title": "Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Cancer", "Recurrent Bladder Carcinoma", "Recurrent Classical Hodgkin Lymphoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Renal Cell Carcinoma", "Stage III Bladder Cancer", "Stage III Lymphoma", "Stage III Non-Small Cell Lung Cancer AJCC v7", "Stage III Renal Cell Cancer", "Stage III Skin Melanoma", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7", "Stage IIIA Skin Melanoma", "Stage IIIB Non-Small Cell Lung Cancer AJCC v7", "Stage IIIB Skin Melanoma", "Stage IIIC Skin Melanoma", "Stage IV Bladder Cancer", "Stage IV Lymphoma", "Stage IV Non-Small Cell Lung Cancer AJCC v7", "Stage IV Renal Cell Cancer", "Stage IV Skin Melanoma", "Stage IVA Bladder Cancer", "Stage IVB Bladder Cancer", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Enzyme Inhibitor Therapy", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2017-10-03", "completion_date": "2022-10-30", "has_results": true, "last_update_posted_date": "2023-12-06", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03229278" }, { "nct_id": "NCT02782715", "title": "Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Stereotactic Body Radiation Therapy (SBRT)", "type": "RADIATION" }, { "name": "Microwave Ablation (MWA)", "type": "PROCEDURE" } ], "intervention_types": [ "RADIATION", "PROCEDURE" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2018-06-28", "completion_date": "2023-01-10", "has_results": true, "last_update_posted_date": "2024-03-20", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02782715" }, { "nct_id": "NCT05269381", "title": "Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage III Gastric Cancer AJCC v8", "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage III Merkel Cell Carcinoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IV Merkel Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8", "Locally Advanced Cervical Carcinoma", "Locally Advanced Endometrial Carcinoma", "Locally Advanced Gastric Adenocarcinoma", "Locally Advanced Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Head and Neck Squamous Cell Carcinoma", "Locally Advanced Hepatocellular Carcinoma", "Locally Advanced Lung Non-Small Cell Carcinoma", "Locally Advanced Malignant Solid Neoplasm", "Locally Advanced Melanoma", "Locally Advanced Merkel Cell Carcinoma", "Locally Advanced Renal Cell Carcinoma", "Locally Advanced Skin Squamous Cell Carcinoma", "Locally Advanced Triple-Negative Breast Carcinoma", "Locally Advanced Unresectable Breast Carcinoma", "Locally Advanced Unresectable Cervical Carcinoma", "Locally Advanced Unresectable Gastric Adenocarcinoma", "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma", "Locally Advanced Unresectable Renal Cell Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Cervical Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Gastric Adenocarcinoma", "Metastatic Gastroesophageal Junction Adenocarcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Merkel Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Metastatic Skin Squamous Cell Carcinoma", "Metastatic Triple-Negative Breast Carcinoma", "Metastatic Urothelial Carcinoma", "Skin Squamous Cell Carcinoma", "Stage III Cervical Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8", "Triple-Negative Breast Carcinoma", "Unresectable Cervical Carcinoma", "Unresectable Endometrial Carcinoma", "Unresectable Gastric Adenocarcinoma", "Unresectable Gastroesophageal Junction Adenocarcinoma", "Unresectable Head and Neck Squamous Cell Carcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Lung Non-Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Melanoma", "Unresectable Merkel Cell Carcinoma", "Unresectable Renal Cell Carcinoma", "Unresectable Skin Squamous Cell Carcinoma", "Unresectable Triple-Negative Breast Carcinoma", "Unresectable Urothelial Carcinoma", "Breast Adenocarcinoma", "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Neoantigen Peptide Vaccine", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 132, "start_date": "2022-03-31", "completion_date": "2028-03-31", "has_results": false, "last_update_posted_date": "2026-03-12", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269381" }, { "nct_id": "NCT00091611", "title": "Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Neoplasms" ], "interventions": [ { "name": "IL-2 (interleukin-2)", "type": "DRUG" }, { "name": "OKT3", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2004-09", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2012-10-26", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00091611" }, { "nct_id": "NCT06682793", "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Non-Small Cell Lung", "NSCLC (Non-small Cell Lung Cancer)", "Cancer", "Colon Cancer", "Rectal Cancer", "Lung Cancer", "CRC", "Head and Neck Squamous Cell Cancer", "HNSCC", "Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Triple Negative Breast Cancer", "TNBC", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "A2B395", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2025-05-22", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-07T19:33:20.842Z", "location_count": 10, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682793" } ] }